Finch Therapeutics Group Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6
- Today's High:
- $6.455
- Open Price:
- $6.1887
- 52W Low:
- $5.6
- 52W High:
- $86.7
- Prev. Close:
- $6.2899
- Volume:
- 5336
Company Statistics
- Market Cap.:
- $10.22 million
- Book Value:
- 17.382
- Revenue TTM:
- $253000
- Operating Margin TTM:
- -29407.12%
- Gross Profit TTM:
- $-57032000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.51%
- Return on Equity TTM:
- -146.19%
Company Profile
Finch Therapeutics Group Inc had its IPO on 2021-03-19 under the ticker symbol FNCH.
The company operates in the Healthcare sector and Biotechnology industry. Finch Therapeutics Group Inc has a staff strength of 18 employees.
Stock update
Shares of Finch Therapeutics Group Inc opened at $6.19 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6 - $6.46, and closed at $6.13.
This is a -2.54% slip from the previous day's closing price.
A total volume of 5,336 shares were traded at the close of the day’s session.
In the last one week, shares of Finch Therapeutics Group Inc have slipped by -2.85%.
Finch Therapeutics Group Inc's Key Ratios
Finch Therapeutics Group Inc has a market cap of $10.22 million, indicating a price to book ratio of 0.3623 and a price to sales ratio of 23.383.
In the last 12-months Finch Therapeutics Group Inc’s revenue was $253000 with a gross profit of $-57032000 and an EBITDA of $-70163000. The EBITDA ratio measures Finch Therapeutics Group Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Finch Therapeutics Group Inc’s operating margin was -29407.12% while its return on assets stood at -31.51% with a return of equity of -146.19%.
In Q2, Finch Therapeutics Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 69.8%.
Finch Therapeutics Group Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-85.65 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Finch Therapeutics Group Inc’s profitability.
Finch Therapeutics Group Inc stock is trading at a EV to sales ratio of 6.5371 and a EV to EBITDA ratio of -0.1324. Its price to sales ratio in the trailing 12-months stood at 23.383.
Finch Therapeutics Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $66.86 million
- Total Liabilities
- $9.58 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Finch Therapeutics Group Inc ended 2025 with $66.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $66.86 million while shareholder equity stood at $27.89 million.
Finch Therapeutics Group Inc ended 2025 with $0 in deferred long-term liabilities, $9.58 million in other current liabilities, 2000.00 in common stock, $-344938000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $34.05 million and cash and short-term investments were $34.05 million. The company’s total short-term debt was $1,656,000 while long-term debt stood at $0.
Finch Therapeutics Group Inc’s total current assets stands at $36.50 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $432000.00 and inventory worth $0.
In 2025, Finch Therapeutics Group Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Finch Therapeutics Group Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $6.13
- 52-Week High
- $86.7
- 52-Week Low
- $5.6
- Analyst Target Price
- $150
Finch Therapeutics Group Inc stock is currently trading at $6.13 per share. It touched a 52-week high of $86.7 and a 52-week low of $86.7. Analysts tracking the stock have a 12-month average target price of $150.
Its 50-day moving average was $7.57 and 200-day moving average was $12.08 The short ratio stood at 2.19 indicating a short percent outstanding of 0%.
Around 5088.1% of the company’s stock are held by insiders while 1979.2% are held by institutions.
Frequently Asked Questions About Finch Therapeutics Group Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.